欲增资控股芯片测试公司 002077股价“抢跑”
Shang Hai Zheng Quan Bao· 2025-11-03 23:01
Core Viewpoint - Dagang Co., Ltd. plans to invest 90 million yuan through its wholly-owned subsidiary, Shanghai Minai Semiconductor Co., Ltd., to increase the registered capital of Jiangsu Aike Integrated Circuit Co., Ltd. and gain control over it [2][3][5] Investment Details - The investment involves an increase in registered capital of 37.15 million yuan, with the remaining amount added to the capital reserve of Aike Integrated [3] - After the capital increase, Aike Integrated's registered capital will rise from 10 million yuan to 47.15 million yuan, with Shanghai Minai holding 78.79% of the shares, making Aike Integrated a subsidiary [5] Market Reaction - Following the announcement, Dagang's stock price experienced unusual fluctuations, with a trading volume of 1.078 billion yuan and a turnover rate of 10.84% on November 3 [6] Business Synergy - Aike Integrated focuses on integrated circuit testing, aligning with Shanghai Minai's main business, and aims to enhance strategic cooperation with core clients, thereby promoting growth in the integrated circuit testing sector [7][8] Financial Performance - Aike Integrated reported a net profit of 1.5928 million yuan in the first half of 2025, with a total revenue of 20.8923 million yuan [10] - The net asset value of Aike Integrated is 11.509 million yuan, with an assessed value of 24.2244 million yuan, reflecting a net asset appreciation rate of 110.48% [8][10]
欲增资控股芯片测试公司,002077股价“抢跑”
Shang Hai Zheng Quan Bao· 2025-11-03 23:01
大港股份(002077)11月3日晚公告,拟以全资子公司上海旻艾半导体有限公司(简称"上海旻艾")使用自有资金9000万元增资认缴主 营集成电路测试业务的江苏艾科集成电路有限公司(简称"艾科集成")新增注册资本并实现对其控股。 值得注意的是,公告发布前,基本面并无太多利好的大港股份11月3日午间开盘后股价异动拉升,全天成交10.78亿元,换手率10.84%。 这种情况让投资者不禁疑惑:"聪明钱"是纯属巧合还是精准伏击? 出资9000万元 大港股份欲投资芯片测试公司 进一步来看,艾科集成的客户主要为IC设计单位,且大部分客户资源由股东江苏艾科转接而来。江苏艾科在集成电路测试行业深耕十余 年,拥有较高的品牌影响力,并与行业内多家领先企业保持长期合作关系。 具体来看,大港股份拟以全资子公司上海旻艾使用自有资金9000万元增资认缴艾科集成新增注册资本3715.26万元,剩余部分计入艾科 集成资本公积。 增资完成后,艾科集成的注册资本由1000万元增加至4715.26万元,上海旻艾将持有艾科集成78.79%的股权,艾科集成将成为上海旻艾 的控股子公司,纳入公司合并报表范围。 公告称,艾科集成主营集成电路测试业务,与上海 ...
000851,终止上市,即将摘牌
Zheng Quan Shi Bao· 2025-11-03 22:59
Core Viewpoint - *ST Gaohong (000851) has received a decision from the Shenzhen Stock Exchange to terminate its listing due to its stock price being below 1 yuan for twenty consecutive trading days, leading to its direct delisting without a transition period [1][3]. Group 1: Company Overview - *ST Gaohong, officially known as 大唐高鸿网络股份有限公司, was established by the China Academy of Telecommunications Technology (Datang Telecom Group) [3]. - The company has developed three main business segments: digital application, information services, and IT sales over its more than twenty years of listing [3]. - At its peak, *ST Gaohong reported revenue exceeding 7 billion yuan, with 2023 revenue recorded at 5.93 billion yuan and total assets at 8.3 billion yuan [3]. Group 2: Financial Irregularities - The China Securities Regulatory Commission identified that from 2015 to 2021, *ST Gaohong engaged in fraudulent trade activities through its subsidiary, Beijing Datang Gaohong Technology Co., Ltd., involving a company controlled by Jiang Qing [4]. - These fraudulent activities resulted in inflated revenue and profits in annual reports, with 2019 alone seeing an inflated revenue of 5.634 billion yuan, accounting for nearly half of the reported revenue, and an inflated profit exceeding 20 million yuan [4]. - The company has also faced issues of inflated revenue and profits in its 2022 and 2023 annual reports [4]. Group 3: Shareholder Information - As of the end of the third quarter, *ST Gaohong had over 80,000 shareholders [5].
130亿美元估值!博裕投资拿下星巴克中国至多60%股权 双方成立合资公司
Mei Ri Jing Ji Xin Wen· 2025-11-03 22:52
每经讯 11月4日,星巴克宣布,与博裕投资达成战略合作,双方将成立合资企业,共同运营星巴克在中 国市场的零售业务。 博裕将持有合资企业至多60%股权,星巴克保留40%股权,并将继续作为星巴克品牌与知识产权的所有 者和授权方,向新成立的合资企业进行授权。基于约40亿美元(不计现金与债务)的企业价值,博裕将 获得其相应权益。 星巴克预计其中国零售业务的总价值将超过130亿美元,总价值由三部分构成:向博裕出让合资企业控 股权益所得、星巴克在合资企业中保留的权益价值,以及未来十年或更长时间内持续支付给星巴克的授 权经营收益。 新成立的合资企业将继续以上海为总部,双方将致力于未来将星巴克在中国的门店规模逐步拓展至 20000家。 (文章来源:每日经济新闻) ...
拉近网娱:上市委员会决定维持暂停公司股份买卖的上市科决定
Zhi Tong Cai Jing· 2025-11-03 22:50
拉近网娱(08172)发布公告,董事会谨此知会公司股东及潜在投资者,委员会已于2025年10月21日就上 市科决定举行复核聆讯。于2025年11月3日,公司接获联交所的函件,通知公司,委员会经考虑公司及 上市科提交的所有书面及口头呈件后,认为公司未能根据GEM上市规则第17.26条所规定维持足够的业 务运作及资产水平,以保证公司股份得以继续上市,并决定维持根据GEM上市规则第9.04(3)条暂停买 卖股份的上市科决定。 根据GEM上市规则第4章,公司有权将GEM上市委员会决定提交GEM上市复核委员会复核。根据GEM 上市规则第4.08(1)条,公司可于GEM上市委员会决定发出后7个营业日内(即于2025年11月12日或之前) 要求GEM上市复核委员会复核GEM上市委员会决定。公司现正向其外聘顾问寻求意见,并将考虑是否 提请将GEM上市委员会决定提交GEM上市复核委员会复核。除非公司申请复核GEM上市委员会决定, 否则公司股票将于GEM上市委员会决定日期(即2025年11月13日)起计七个营业日届满后暂停买卖。于决 定是否申请复核GEM上市委员会决定前,公司股份将继续买卖。 ...
拉近网娱(08172):上市委员会决定维持暂停公司股份买卖的上市科决定
智通财经网· 2025-11-03 22:48
拉近网娱(08172)发布公告,董事会谨此知会公司股东及潜在投资者,委员会已于2025年10月21日就上 市科决定举行复核聆讯。于2025年11月3日,公司接获联交所的函件,通知公司,委员会经考虑公司及 上市科提交的所有书面及口头呈件后,认为公司未能根据GEM上市规则第17.26条所规定维持足够的业 务运作及资产水平,以保证公司股份得以继续上市,并决定维持根据GEM上市规则第9.04(3)条暂停买 卖股份的上市科决定。 根据GEM上市规则第4章,公司有权将GEM上市委员会决定提交GEM上市复核委员会复核。根据GEM 上市规则第4.08(1)条,公司可于GEM上市委员会决定发出后7个营业日内(即于2025年11月12日或之前) 要求GEM上市复核委员会复核GEM上市委员会决定。公司现正向其外聘顾问寻求意见,并将考虑是否 提请将GEM上市委员会决定提交GEM上市复核委员会复核。除非公司申请复核GEM上市委员会决定, 否则公司股票将于GEM上市委员会决定日期(即2025年11月13日)起计七个营业日届满后暂停买卖。于决 定是否申请复核GEM上市委员会决定前,公司股份将继续买卖。 ...
加密市场一度闪崩!24小时内超85亿元爆仓;美联储官员密集发声;水贝金价大涨 周大福金饰价格调整丨每经早参
Mei Ri Jing Ji Xin Wen· 2025-11-03 22:47
Market Overview - US stock indices closed mixed, with the Nasdaq up 0.46% and the S&P 500 up 0.17%, while the Dow Jones fell 0.48% [4] - Amazon reached a historical high, rising approximately 4%, while Tesla and Nvidia increased over 2% [4] - The Nasdaq China Golden Dragon Index rose 0.26%, with mixed performance among Chinese concept stocks [5] Federal Reserve Insights - Federal Reserve officials expressed openness to interest rate cuts, with Daly supporting a 50 basis point reduction this year [5] - Milan emphasized that the current policy is overly restrictive and suggested a series of 50 basis point cuts [5] - Cook noted that monetary policy is not on a fixed path and will depend on upcoming data [5] Cryptocurrency Market - Bitcoin dropped below $105,400, down over $5,000 from its daily high, while Ethereum fell nearly 9% [6] - Over $1.2 billion in positions were liquidated in the crypto market within 24 hours, primarily affecting long positions [6] Commodity Prices - International gold prices rose slightly, with spot gold at $4,005.31 per ounce [7] - WTI crude oil futures increased by 0.11% to $61.05 per barrel [7] Corporate Developments - Geely acquired a 26.4% stake in Renault's Brazilian operations, allowing it to share resources while Renault remains the controlling shareholder [18] - TSMC plans to implement a price increase of 3% to 5% for advanced processes below 5nm starting January 2026, reflecting strong demand in AI and HPC sectors [20] - Weima Automotive announced potential recovery plans after filing for bankruptcy, with new investments aimed at resuming production [30] Financial Sector Updates - Industrial and Commercial Bank of China (ICBC) and China Construction Bank resumed gold-related services after a brief suspension [16] - The People's Bank of China and the Bank of Korea renewed a bilateral currency swap agreement worth 400 billion RMB [9] Regulatory and Policy Changes - The Chinese government extended visa-free policies for France and other countries until the end of 2026 [10] - New immigration policies were announced to facilitate travel between mainland China and Hong Kong, Macau, and Taiwan [10]
维立志博-B(09887.HK)研究摘要入选第67届ASH年会展示
Ge Long Hui· 2025-11-03 22:45
公司已连续多年在ASH、美国临床肿瘤学会(ASCO)等国际舞台上发表创新药研发成果。此次多项研究 成果集中入选第67届ASH年会,代表了国际学术界对公司科研创新实力的高度认可。 格隆汇11月4日丨维立志博-B(09887.HK)发布公告,有关5篇研究摘要入选美国血液学会("ASH")以于其 第67届年会上展示。公司提供有关其在研创新药LBL-034及LBL-076的进一步详情,该等药物的多份研 究摘要已被第67届ASH年会收录。其中,1项LBL-034临床研究获选在大会首日作第一个口头报告,展 示LBL-034对复发╱难治性多发性骨髓瘤患者的最新疗效及安全性数据。 ...
维立志博-B:1项LBL-034临床研究获选在第67届ASH年会首日作第一个口头报告
Zhi Tong Cai Jing· 2025-11-03 22:44
维立志博-B(09887)发布公告,内容有关5篇研究摘要入选美国血液学会以于其第67届年会上展示。公司 欣然提供有关其在研创新药LBL-034及LBL-076的进一步详情,该等药物的多份研究摘要已被第67届 ASH年会收录。其中,1项LBL-034临床研究获选在大会首日作第一个口头报告,展示LBL-034对复发╱ 难治性多发性骨髓瘤患者的最新疗效及安全性数据。 ...
维立志博-B(09887):1项LBL-034临床研究获选在第67届ASH年会首日作第一个口头报告
智通财经网· 2025-11-03 22:40
智通财经APP讯,维立志博-B(09887)发布公告,内容有关5篇研究摘要入选美国血液学会以于其第67届 年会上展示。公司欣然提供有关其在研创新药 LBL-034及LBL-076的进一步详情,该等药物的多份研究 摘要已被第67届ASH年会收录。其中,1项LBL-034临床研究获选在大会首日作第一个口头报告,展示 LBL-034对复发╱难治性多发性骨髓瘤患者的最新疗效及安全性数据。 ...